ENOVID-E 21 Drug Patent Profile
When do Enovid-e 21 patents expire, and what generic alternatives are available?
Enovid-e 21 is a drug marketed by Gd Searle Llc and is included in one NDA.
The generic ingredient in ENOVID-E 21 is mestranol; norethynodrel. There is one drug master file entry for this compound. Additional details are available on the mestranol; norethynodrel profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ENOVID-E 21?
- What are the global sales for ENOVID-E 21?
- What is Average Wholesale Price for ENOVID-E 21?
Summary for ENOVID-E 21
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Patent Applications: | 1 |
| DailyMed Link: | ENOVID-E 21 at DailyMed |
US Patents and Regulatory Information for ENOVID-E 21
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gd Searle Llc | ENOVID-E 21 | mestranol; norethynodrel | TABLET;ORAL-21 | 010976-007 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
